Results for: GLP-1

Kourtney Kardashian Barker’s wellness brand, Lemme, is launching a plant-based supplement called GLP-1 Daily, marketed as a natural alternative to Ozempic. While experts are skeptical of its effectiveness compared to prescription GLP-1 medications, they acknowledge its potential benefits for regulating blood sugar, fighting visceral fat, and reducing inflammation. The supplement aims to provide a more accessible and natural option for those seeking similar benefits to Ozempic, but without the side effects.

Vivani Medical, Inc. (VANI) announced promising preclinical results for its exenatide implant, demonstrating a significant reduction in liver fat in obese mice. This implant, which delivers the drug exenatide (sold as Byetta and Bydureon for diabetes), could potentially offer a highly differentiated treatment option for obesity and related metabolic disorders. Vivani is preparing to launch its first human clinical trial, LIBERATE-1, later this year.

The widespread adoption of Ozempic and similar GLP-1 weight loss drugs has triggered a seismic shift in the fashion and food industries. This article explores how these medications are impacting resale markets, reshaping consumer buying habits, and driving new strategies in the food and beverage sectors.

Roundhill Investments CEO Dave Mazza sees a strong parallel between Eli Lilly’s dominance in the weight loss drug market and Nvidia’s leadership in the AI space. He highlights Eli Lilly’s robust earnings growth and consistent exceeding of forecasts, fueled by high demand and limited supply. This has led to a strong stock performance despite market volatility, although Mazza cautions about potential risks if sales growth doesn’t meet expectations.

Telehealth company Hims & Hers Health Inc (HIMS) has seen its stock skyrocket over 120% since August 2023, outperforming industry giants like Eli Lilly and Novo Nordisk, driven by its compounded alternatives to popular GLP-1 weight-loss treatments. This surge comes amidst explosive demand and supply shortages for drugs like Wegovy, Ozempic, and Mounjaro, highlighting a lucrative market opportunity for Hims. Despite concerns about safety and legal challenges, Hims’ affordable price point and secure supply chain have fueled consumer interest.

Novo Nordisk has provided updates on its insulin and GLP-1 product lines. Following a previous announcement of price reductions, the company has discontinued the basal insulin Levemir.

Weight loss drugs known as GLP-1s, including Ozempic, have a surprising impact on tobacco and alcohol habits. Studies indicate that GLP-1 users reduce their consumption of both substances while taking the medications. This observation suggests a potential positive effect on addictive behaviors, prompting further research to explore the causal link.